Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04344535 · ClinicalTrials.gov registry record · Phase 1
Convalescent Plasma vs. Standard Plasma for COVID-19
A Phase 1 study, sponsored by Stony Brook University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
NCT04344535 is a Phase 1 study that was terminated before completion, run by Stony Brook University. The registered enrollment target is 82 participants.
The verdict
NCT04344535, a Phase 1 study, was terminated before completion, sponsored by Stony Brook University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if transfusion of blood plasma containing antibodies against COVID-19 (anti-SARS-CoV-2), which were donated from a patient who recovered from COVID-19 infection, is safe and can treat COVID-19 in hospitalized patients. Antibodies are blood proteins produced by the body in response to a virus and can remain in the person's bloodstream (plasma) for a long time after they recover. Transferring plasma from a person who recovered from COVID-19 may help neutralize the virus in sick patients' blood, and/or reduce the chances of the infection getting worse.
Interventions
- BIOLOGICAL Convalescent Plasma
- BIOLOGICAL Standard Donor Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2020-04-08 |
| Est. Completion | 2021-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04344535
The ClinicalTrials.gov registry entry for NCT04344535 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Convalescent Plasma is the first listed.
NCT04344535 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04344535 about?
NCT04344535 is a clinical study titled "Convalescent Plasma vs. Standard Plasma for COVID-19". The purpose of this study is to find out if transfusion of blood plasma containing antibodies against COVID-19 (anti-SARS-CoV-2), which were donated from a patient who recovered from COVID-19 infection, is safe and can treat COVID-19 in hospitalized patients. Antibodies are blood proteins produced ...
What is the current status of trial NCT04344535?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2020-04-08. Estimated completion is 2021-02-01.
What interventions are being tested in trial NCT04344535?
The interventions under investigation include: Convalescent Plasma (BIOLOGICAL), Standard Donor Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04344535?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.